Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)
NCT00469053 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2007-11-16
Summary
The purpose of this study is to determine whether two different analgesic transdermal patch formulations lead to same plasma levels of active ingredient after multiple dose application.
Conditions
- Healthy
Interventions
- DRUG
-
Buprenorphine
Sponsors & Collaborators
-
Grünenthal GmbH
lead INDUSTRY
Principal Investigators
-
Wolfgang Timmer, Dr. · CRS Clinical Research Services Mannheim
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-05-31
- Completion
- 2007-11-30
Countries
- Germany
Study Locations
More Related Trials
-
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
NCT00857428 ·Status: COMPLETED ·Phase: PHASE1
-
Transversus Abdominis Plane Block For Renal Transplant Recipients
NCT00905957 ·Status: COMPLETED ·Phase: NA
-
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
NCT03137030 ·Status: WITHDRAWN ·Phase: PHASE1
-
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
NCT01631513 ·Status: WITHDRAWN ·Phase: PHASE4
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability
NCT00986258 ·Status: TERMINATED ·Phase: PHASE3
-
To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01101178 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen
NCT03567941 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100320 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
NCT02603705 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
NCT00763321 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
NCT02151682 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain
NCT02367820 ·Status: COMPLETED ·Phase: PHASE3
-
Tapentadol (CG5503)
NCT00421928 ·Status: COMPLETED ·Phase: PHASE3
-
taPentadol cLinical prAcTice IN belgiUM
NCT03814993 ·Status: COMPLETED
-
Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions
NCT01210638 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain
NCT02716857 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
NCT01273532 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01081912 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
NCT01100086 ·Status: COMPLETED ·Phase: PHASE1
-
OTR Tablet 10 mg Fasted-state Bioequivalence Study
NCT03403504 ·Status: COMPLETED ·Phase: PHASE1
-
Conversion to Embeda With Rescue Trial
NCT01179191 ·Status: TERMINATED ·Phase: PHASE4
-
OTR Tablet 40 mg Fed-state Bioequivalence Study
NCT03398330 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.
NCT01725087 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
NCT03137017 ·Status: WITHDRAWN ·Phase: PHASE1